AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7011221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both early and delayed groups
Number of subjects: 36
Study 31709738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 97
Study 31709738 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide modified release 120 mg
Number of subjects: 97
Study 30193295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy (FEC followed by paclitaxel and trastuzumab)
Number of subjects: 280
Study 30193295 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy (Paclitaxel and trastuzumab followed by FEC and trastuzumab)
Number of subjects: 280
Study 29240863 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution, once-daily for 48 weeks, with two 12-week post-treatment follow-ups (at week 60 and 72)
Number of subjects: 23
Study 29240863 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution, once-daily for 48 weeks
Number of subjects: 23
Study 25559903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vertical and horizontal plyometric training (VHG)
Number of subjects: 40
Study 25559903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical plyometric training (VG)
Number of subjects: 40
Study 25559903 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal plyometric training (HG)
Number of subjects: 40
Study 25559903 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study 24126365 — intervention group
Group type: EXPERIMENTAL
Intervention: XPF thyroid collars (TCs)
Number of subjects: 144
Study 24126365 — intervention group
Group type: COMPARATOR
Intervention: Standard 0.5-mm lead-equivalent TCs
Number of subjects: 144
Study 22156827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 99
Study 19399391 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring of blood pressure
Number of subjects: 0
Study 19399391 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring combined with regular individualized interventions (like phone calls)
Number of subjects: 0
Study 19399391 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 17415036 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple nucleosides
Number of subjects: 170
Study 17415036 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-containing regimen
Number of subjects: 170
Study 17415036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 170
Study 15157254 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated RBCs plus unlabeled allogeneic RBCs (1.0 mL of biotinylated RBCs plus 15 mL per kg of unlabeled allogeneic RBCs)
Number of subjects: 0
Study 15157254 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotinylated RBCs
Number of subjects: 0
Study 16492007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year preventive intervention with practice-nurse support for follow-up of elevated risk patients
Number of subjects: 7092
Study 16492007 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving care as usual
Number of subjects: 7092
Study 10227554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley bite plane (HBP)
Number of subjects: 20
Study 10227554 — intervention group
Group type: COMPARATOR
Intervention: superior repositioning splint (SRS)
Number of subjects: 20
Study 9441111 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computer tomography (HRCT) for diagnosis
Number of subjects: 0
Study 9441111 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0
Study 9441111 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive tests for patient stratification
Number of subjects: 0
Study 2072515 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of 1% mepivacaine at a rate of 2 ml.hr‐1
Number of subjects: 40
Study 2072515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus administration of 1% mepivacaine 4-5 times daily
Number of subjects: 40
Study 2072515 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy including infusion of Ringer's solution and diuretics (Control group)
Number of subjects: 40
Study 6653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (i.v. doses of 3, 6, and 12 mg)
Number of subjects: 12
Study 6653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (i.v. doses)
Number of subjects: 12
Study 6653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (oral doses of 40, 80, and 120 mg)
Number of subjects: 12
Study 6653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (oral doses)
Number of subjects: 12
Study 6653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (i.v. administration)
Number of subjects: 12
Study 6653649 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (all doses)
Number of subjects: 12
Study 6653649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31970794 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D dosimeter, PRESAGE, irradiated under various gantry and couch angles with 6 MV at 800 MU/field.
Number of subjects: 0
Study 31849296 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote counselling by phone (Group 1)
Number of subjects: 120
Study 31849296 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote counselling via text messages (Group 2)
Number of subjects: 120
Study 31849296 — intervention group
Group type: COMPARATOR
Intervention: Standard advice from attending physicians (Group 3)
Number of subjects: 120
Study 28323806 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pain management plus perioperative nonsteroidal anti-inflammatory drugs
Number of subjects: 0
Study 28323806 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pain management plus pregabalin
Number of subjects: 0
Study 28323806 — intervention group
Group type: COMPARATOR
Intervention: Standard pain management
Number of subjects: 0
Study 27581760 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary program group
Number of subjects: 256
Study 27581760 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized care group
Number of subjects: 256
Study 25091090 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW)
Number of subjects: 752
Study 25091090 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 752
Study 21878834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 338
Study 21878834 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 338
Study 19233766 — intervention group
Group type: EXPERIMENTAL
Intervention: Spyder exoconnector device for clampless proximal anastomosis
Number of subjects: 38
Study 17894653 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Number of subjects: 455
Study 17894653 — intervention group
Group type: COMPARATOR
Intervention: 20 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Number of subjects: 455
Study 14978550 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc chelate 1 mg/kg daily for 3 months
Number of subjects: 40
Study 14978550 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 40
Study 11915705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous infusion technique
Number of subjects: 87
Study 11915705 — intervention group
Group type: COMPARATOR
Intervention: Traditional drugs
Number of subjects: 87
Study 9658754 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool myeloperoxidase levels in active inflammatory bowel disease patients
Number of subjects: 89
Study 9658754 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool myeloperoxidase levels after resolution of disease exacerbation
Number of subjects: 89
Study 9658754 — intervention group
Group type: COMPARATOR
Intervention: Stool myeloperoxidase levels in normal controls
Number of subjects: 89
Study 9658754 — intervention group
Group type: COMPARATOR
Intervention: Stool myeloperoxidase levels in inflammatory disease controls
Number of subjects: 89
Study 8085688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g orally every 6 hours)
Number of subjects: 300
Study 8085688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (continuous intravenous, titrated to maintain gastric pH at 4.0)
Number of subjects: 300
Study 8085688 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control)
Number of subjects: 300
Study 29554208 — intervention group
Group type: COMPARATOR
Intervention: Compliant ads
Number of subjects: 120
Study 29554208 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliant ads
Number of subjects: 120
Study 29554208 — intervention group
Group type: COMPARATOR
Intervention: User engagement and UGCs
Number of subjects: 120
Study 29554208 — intervention group
Group type: COMPARATOR
Intervention: AUDIT scores
Number of subjects: 120
Study 29554208 — intervention group
Group type: COMPARATOR
Intervention: Facebook involvement scores
Number of subjects: 120
Study 28487349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centred Innovations for Persons with Multimorbidity (details on specific interventions not provided)
Number of subjects: 0
Study 28487349 — intervention group
Group type: COMPARATOR
Intervention: Control group matched on age, sex, enrolment/index date and propensity score (details on specific interventions not provided)
Number of subjects: 0
Study 25134858 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized preventive care measures
Number of subjects: 610
Study 23165743 — intervention group
Group type: COMPARATOR
Intervention: Multifraction radiotherapy (MFRT) - 30 Gy in 10 fractions
Number of subjects: 235
Study 23165743 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (SFRT) - 8 Gy in 1 fraction
Number of subjects: 235
Study 20875040 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptive language disorders
Number of subjects: 6051
Study 20875040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic disorders
Number of subjects: 6051
Study 20875040 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected autism
Number of subjects: 6051
Study 19712155 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin emulsifiable concentrate (EC)
Number of subjects: 0
Study 19712155 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin suspension concentrate (SC)
Number of subjects: 0
Study 17043157 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (0.7 mug/kg per hour for 10 hours followed by 0.9 mug/kg per hour for 4 hours)
Number of subjects: 25
Study 17043157 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (2 ng/kg per minute) during placebo
Number of subjects: 25
Study 17043157 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (2 ng/kg per minute) during spironolactone (50 mg per day)
Number of subjects: 25
Study 17043157 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone (50 mg per day)
Number of subjects: 25
Study 12556676 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 302
Study 12556676 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 302
Study 10675427 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm for 24 hours, then 5 ppm for 96 hours)
Number of subjects: 248
Study 10675427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitric oxide)
Number of subjects: 248
Study 10675427 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 248
Study 9479662 — intervention group
Group type: EXPERIMENTAL
Intervention: Destruction of T2 ganglion with intact T3 ganglion
Number of subjects: 20
Study 9479662 — intervention group
Group type: COMPARATOR
Intervention: Destruction of T3 ganglion with intact T2 ganglion
Number of subjects: 20
Study 9479662 — intervention group
Group type: EXPERIMENTAL
Intervention: Destruction of both T2 and T3 ganglia
Number of subjects: 20
Study 9479662 — intervention group
Group type: COMPARATOR
Intervention: Stellate stimulation
Number of subjects: 20
Study 12959319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin intravenously (i.v.) over 3-5 min
Number of subjects: 18
Study 12959319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin i.v. over 3-5 min followed by ticarcillin infused i.v. over 20-30 min
Number of subjects: 18
Study 12959319 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin alone (TOB phase)
Number of subjects: 18
Study 3032490 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH therapy
Number of subjects: 35
Study 3032490 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 35
Study 3032490 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MS
Number of subjects: 35
Study 31563977 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Number of subjects: 50
Study 31563977 — intervention group
Group type: EXPERIMENTAL
Intervention: Glossotonsillar sulcus infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Number of subjects: 50
Study 30053199 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment according to a pre-defined algorithm in a tight control regimen
Number of subjects: 222
Study 27513278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus therapy for 2 years at doses adjusted to maintain a trough blood level of 5-15 ng/ml
Number of subjects: 63
Study 25479899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MR or PE
Number of subjects: 110
Study 25479899 — intervention group
Group type: COMPARATOR
Intervention: Patients without MR or PE
Number of subjects: 110
Study 25479899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abnormal coronary arteries and MR or PE
Number of subjects: 110
Study 25479899 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MR or PE at 3-week follow-up
Number of subjects: 110
Study 25479899 — intervention group
Group type: COMPARATOR
Intervention: Patients without MR or PE at 3-week follow-up
Number of subjects: 110
Study 22414053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct (PD) stenting following endoscopic sphincterotomy (EST)
Number of subjects: 141
Study 22414053 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST) alone
Number of subjects: 141
Study 20233598 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Cigarette (CC)
Number of subjects: 57
Study 20233598 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically Heated Smoking System (EHCSS)
Number of subjects: 57
Study 20233598 — intervention group
Group type: COMPARATOR
Intervention: No Smoking (NS)
Number of subjects: 57
Study 18803446 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine and donepezil (individually or in combination)
Number of subjects: 9
Study 15950835 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programme (un souffle nouveau)
Number of subjects: 238
Study 12182748 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 5 mg b.d.
Number of subjects: 21
Study 12182748 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 10 mg b.d.
Number of subjects: 21
Study 12182748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12182748 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 2.5 mg b.d.
Number of subjects: 21
Study 12182748 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 (all doses)
Number of subjects: 21
Study 10350664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.05 to 0.3 mg/day)
Number of subjects: 387
Study 10350664 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (5 to 40 mg/day)
Number of subjects: 387
Study 7703043 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (270 to 300 mg/m2 cumulative dose)
Number of subjects: 12
Study 7703043 — intervention group
Group type: COMPARATOR
Intervention: Vincristine and dactinomycin (without doxorubicin)
Number of subjects: 12
Study 1838289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 1301
Study 1838289 — intervention group
Group type: COMPARATOR
Intervention: Control (similar treatment without magnesium)
Number of subjects: 1301
Study 6121518 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuelin Depot
Number of subjects: 20
Study 6121518 — intervention group
Group type: EXPERIMENTAL
Intervention: TheoDur
Number of subjects: 20
Study 31268267 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulator guided rectus sheath block (NS guided RSB)
Number of subjects: 116
Study 31268267 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound guided rectus sheath block (US guided RSB)
Number of subjects: 116
Study 30382824 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX plus MMF (1000-1200 mg/m2/day, maximum 2 g/day, twice daily for 17 months)
Number of subjects: 0
Study 30382824 — intervention group
Group type: COMPARATOR
Intervention: RTX plus placebo
Number of subjects: 0
Study 27583404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT)
Number of subjects: 3055
Study 27583404 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 3055
Study 24355663 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) for 3 months
Number of subjects: 27
Study 24355663 — intervention group
Group type: COMPARATOR
Intervention: Control group (PAD-only)
Number of subjects: 27
Study 24355663 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D+PAD group
Number of subjects: 27
Study 21425387 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS) and Hospital Introduction Sheet (HIS)
Number of subjects: 63
Study 21425387 — intervention group
Group type: COMPARATOR
Intervention: Hospital Introduction Sheet (HIS) only
Number of subjects: 63
Study 20565725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg oral salmon calcitonin (sCT)
Number of subjects: 73
Study 20565725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT)
Number of subjects: 73
Study 20565725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 17384931 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous haemofiltration (CVVH)
Number of subjects: 16
Study 17384931 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended daily dialysis with filtration (EDDf)
Number of subjects: 16
Study 17384931 — intervention group
Group type: COMPARATOR
Intervention: Control group (CVVH)
Number of subjects: 16
Study 16123553 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior hinge flap technique
Number of subjects: 106
Study 16123553 — intervention group
Group type: COMPARATOR
Intervention: Nasal hinge flap technique
Number of subjects: 106
Study 16123553 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective evaluation of dry eye symptoms (OSDI questionnaire) at 1, 3, and 6 months
Number of subjects: 106
Study 14607735 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 100
Study 14607735 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE+MLT (melatonin 20 mg/d orally, 7 days before TACE)
Number of subjects: 100
Study 10563127 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially inflated laryngeal mask (75% volume)
Number of subjects: 60
Study 10563127 — intervention group
Group type: COMPARATOR
Intervention: Deflated laryngeal mask (uninflated)
Number of subjects: 60
Study 7485886 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml isobaric 0.5% bupivacaine intrathecally without aspirating cerebrospinal fluid
Number of subjects: 60
Study 7485886 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml isobaric 0.5% bupivacaine mixed with 1 ml cerebrospinal fluid (total 4 ml)
Number of subjects: 60
Study 7485886 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml isobaric 0.5% bupivacaine mixed with 2 ml cerebrospinal fluid (total 5 ml)
Number of subjects: 60
Study 7485886 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 2258790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 160 mg verapamil with 25 mg hydrochlorothiazide and 50 mg triameterene
Number of subjects: 216
Study 2258790 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 216
Study 2258790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 7218018 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 cc of milk of magnesia plus 5 cc of cascara
Number of subjects: 50
Study 7218018 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 50
Study 31492516 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive CRT (aCRT)
Number of subjects: 39
Study 31492516 — intervention group
Group type: COMPARATOR
Intervention: Echo-guided BiV pacing
Number of subjects: 39
Study 29425477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumac capsules (500 mg/twice daily)
Number of subjects: 30
Study 27380614 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic marking with purified carbon particles (n=20)
Number of subjects: 40
Study 27380614 — intervention group
Group type: COMPARATOR
Intervention: No marking (n=20)
Number of subjects: 40
Study 24568125 — intervention group
Group type: EXPERIMENTAL
Intervention: HEIA-intervention (school-based multiple-behaviour study)
Number of subjects: 1418
Study 24568125 — intervention group
Group type: COMPARATOR
Intervention: Parental regulation (reported by parents and adolescents)
Number of subjects: 1418
Study 24568125 — intervention group
Group type: COMPARATOR
Intervention: Parental regulation (reported by parents)
Number of subjects: 1418
Study 22085227 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks
Number of subjects: 100
Study 22085227 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy alone for 4 weeks
Number of subjects: 100
Study 20846487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium iodide associated to salicylic acid (SISA)
Number of subjects: 40
Study 20846487 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 40